In the frame of a collaborative project with the company NEOVACS (Paris, France), a postdoctoral position is available for studies on anti-allergic vaccination. Two different vaccines targeting endogenous proteins have already been generated (one patented against IL-4 and IL-13; another patent filed). Studies will employ unique transgenic mouse models expressing the human protein targets, vaccination and induction of allergy models. Analyses will include plethysmography, histology, flow cytometry, and evaluation of the B and T cell responses generated after vaccination. The aim is to identify the mechanisms of actions of these two vaccines and potential safety issues.



Highly motivated candidates with a proven track record of excellent scientific accomplishments are encouraged to apply. Applicants should hold a PhD or MD/PhD degree in Immunology. Expertise in mouse vivo models is necessary.  Previous hands-on experience on immunological techniques such as histology, flow cytometry, cell culture is expected. Experience in protein chemistry, vaccination, B cell biology, ELISA, ELISpot is a plus. Good communication skills are essential in French or in English.

Successful candidates will join an interdisciplinary and collaborative team working with clinical and industrial partners to develop next generation diagnostics and immunotherapeutics. The postdoctoral fellow will be weekly involved in the scientific interactions/meetings with NEOVACS and other collaborating labs.

Applications will be considered until the position is filled, but start dates between Jan 1, 2021-March 1,2021 are expected. The position is available for an initial period of 18 months with a possible extension up to 36 months.

Please send your application (including a letter of motivation, curriculum vitae, names + contact information of two referees) as a single PDF file to Dr. Pierre Bruhns (